Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME versus FORTAZ IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME versus FORTAZ IN PLASTIC CONTAINER.
CEFOTAXIME vs FORTAZ IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It is a third-generation cephalosporin with broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.
1-2 g IV every 6-8 hours; maximum 12 g/day. For uncomplicated infections: 1 g IV every 8-12 hours.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
Clinical Note
moderateCefotaxime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotaxime."
Clinical Note
moderateCefotaxime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotaxime."
Clinical Note
moderateWarfarin + Cefotaxime
"Warfarin may increase the anticoagulant activities of Cefotaxime."
Clinical Note
moderatePhenprocoumon + Cefotaxime
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function. In neonates, it is prolonged to 2-4 hours. In severe renal impairment (CrCl <20 mL/min), half-life extends up to 10-15 hours, requiring dose adjustment.
1.8 hours in normal adults; prolonged to 3-5 hours in neonates and 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Approximately 80-90% of the dose is excreted unchanged in the urine via glomerular filtration and tubular secretion. About 5-10% is excreted in bile and feces as desacetylcefotaxime, the active metabolite.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefotaxime."